The Company previously entered into an engagement agreement with CB Capital Partners in which CB Capital Partners will serve as financial advisor in connection with the preparation of an Initiatio ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company ...
EMERYVILLE, Calif., March 05, 2025--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback